Testing

In March 2018, Mayo Medical Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

In February 2018, Mayo Medical Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against multiple myeloma.

In January 2018, Mayo Medical Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

With more than 70,000 uses worldwide and policy endorsements for its use (JAMA Article), the Mayo Clinic Statin Choice Decision-Aid tool is helping patients and their clinicians have meaningful conversations about whether or not to use statins to reduce cardiovascular risk.

In December 2017, Mayo Medical Laboratories announced seven new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Discovery's Edge, Mayo Clinic's research magazine, recently highlighted how new tests are developed in Mayo Clinic’s Neuroimmunology Laboratory.

In October 2017, Mayo Medical Laboratories announced eight new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.

In September 2017, Mayo Medical Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Mayo Clinic and National Decision Support Company unveil CareSelect Lab™ to provide real-time medical guidance when ordering clinical lab tests. The tool assists health care providers with appropriate ordering of lab testing, improving patient care and reducing wasteful spending.

In August 2017, Mayo Medical Laboratories announced a new test along with numerous reference value changes, obsolete tests, and algorithm changes.

Devin Oglesbee, Ph.D., Director of the Biochemical and Molecular Genetics Laboratories at Mayo Clinic, provides an overview of the lysosomal storage disease panel, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.